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Assessment of human health risks of environmental agents has often been limited to consideration
of the potential for the agent to cause cancer or general systemic toxicity after long-term expo-
sure. The U.S. Environmental Protection Agency (U.S. EPA) is increasingly moving toward the
development of integrated assessments, which consider all potential health end points including
developmental toxicity, neurotoxicity, immunotoxicity, reproductive effects, and germ cell muta-
genicity. The U.S. EPA has a responsibility to assess risks to nonhuman species or ecosystems
when appropriate data are available. An example of a recent integrated human health and ecologi-
cal risk assessment can be found in the U.S. EPA Mercury Study Report to Congress. This report
covers the following topics in separate volumes: an inventory of anthropogenic mercury emis-
sions in the United States; an exposure assessment using measured and predicted values and
including indirect dietary exposure; an evaluation of human health risks; an assessment of
ecologic risk wherein water criteria are presented for several wildlife species; an overall integrated
characterization of human and nonhuman risk; and a discussion of risk management considera-
tions. In the evaluation of human health risk, genetic toxicology data were considered for three
forms of mercury: elemental, inorganic (divalent), and methylmercury. These data were used in
judgments of two types of potential health effects (carcinogenicity and germ cell mutagenicity). In
assessment of potential carcinogenicity of inorganic and methylmercury, genetic toxicity data
were key. Data for clastogenicity in the absence of mutagenicity supported the characterization of
inorganic and methylmercury as materials that produce carcinogenic effects only at high, toxic
doses. The evidence for clastogenicity, coupled with information on metabolism and distribution,
resulted in a judgment of a moderate degree of concern (or weight of evidence) that inorganic
mercury can act as a human germ cell mutagen. For methylmercury, the degree of concern for
germ cell mutagenicity is high. Environ Health Perspect 104(Suppl 3):663-673 (1996)
Key words: risk assessment, germ cell mutagenicity, mercury, carcinogenicity, genetic
toxicology
Introduction
Risk assessments done by the U.S.
Environmental Protection Agency (U.S.
EPA) follow the paradigm established by
the National Academy of Sciences (1).
This entails a series ofinterconnected steps
including hazard identification, dose-
response assessment, exposure assessment,
and risk characterization, which are briefly
described below.
Hazard identification uses available
data on biological end points related to a
material to determine if that material is
likely to pose a hazard to human health.
These data are also used to define the type
ofpotential hazard; that is, does the mater-
ial induce tumor formation, cause develop-
mental effects, act as a kidney toxicant, and
so forth.
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In the dose-response assessment, data
from human and animal studies are used to
estimate the amount of material that is
expected to produce a given effect in
humans. In this step it is generally neces-
sary to apply mathematical models to the
data to calculate a quantitative risk estimate
usable for low-dose exposure.
The exposure assessment seeks to deter-
mine the extent to which a population is
exposed to the material. Exposure assess-
ment uses available data relevant to popu-
lation exposure, such as emission data,
measurement of the material in environ-
mental media, and biomarker information.
Fate and transport of the material in the
environment, routes ofexposure, and phar-
macokinetics of the material once in the
body may be considered in the exposure
assessment. Data limitations on the popu-
lations ofinterest often necessitate the use
of modeling to provide relevant estimates
ofexposure.
Risk characterization is the last step of
the risk assessment process. This step evalu-
ates assessments of human health and
ecological effects, identifies human subpop-
ulations or ecological species potentially at
risk, and delineates areas of uncertainty,
limitations, and assumptions made in the
risk assessment.
The U.S. EPA has published guidelines
to provide for consistency ofapplication
and communication of risk assessment.
These guidelines are for assessment of
developmental effects, germ cell muta-
genicity, carcinogenic effects, and expo-
sure and effects of chemical mixtures.
Guidelines are also in place for assessment
ofreproductive effects and are in prepara-
tion for assessment of effects on other
organ systems.
Despite the availability ofguidelines on
assessment ofmultiple end points, empha-
sis until recently has been on assessment of
carcinogenicity, sometimes to the exclusion
of other important types of toxicity. The
U.S. EPA has been reversing this trend on
the advice ofpublications such as the recent
NRC/NAS report Science andJudgment in
RiskAssessment(2). That report emphasizes
that the goal of risk characterization is to
provide understanding of the type and
magnitude ofpotential adverse effects ofan
agent under the particular circumstances of
its release. This directs the U.S. EPA to con-
sider timing ofeffects and end points other
than cancer. A contemporary risk assess-
ment publication (3) stresses the need for
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risk assessment to evaluate in an integrated
fashion all potential hazards posed by
an agent.
An example ofan integrated assessment
is the Mercury Study Report to Congress,
which will be released by the U.S. EPA
in 1996. This study was done as part of
the requirements of the Clean Air Act
Amendments of 1990 (4) which specified
the following:
The Administrator shall conduct, and
transmit to the Congress not later than 4
years after the date of enactment of the
Clean Air Act Amendments of 1990, a
study ofmercury emissions from electric
utility steam generating units, municipal
waste combustion units, and other
sources, including area sources. Such
study shall consider the rate and mass of
such emissions, the health and environ-
mental effects of such emissions, tech-
nologies which are available to control
such emissions, and the costs of such
technologies.
In response to this mandate, the U.S.
EPA prepared a seven-volume Mercury
Study Report to Congress, which included
the following: an inventory of anthro-
pogenic emissions in the United States, a
nationwide exposure assessment, an assess-
ment of human health risks from three
forms ofmercury, an assessment ofwildlife
hazard from mercury, and a characteriza-
tion of risk that compared and integrated
potential hazard to human and nonhuman
species. The report concludes with an eval-
uation of control technologies, costs of
implementation, and an estimate ofsome
social costs ofmercury pollution.
The human health risk assessment
made use of the applicable guidelines and
standard risk assessment procedures for
evaluation of cancer risk, developmental
toxicity, germ cell mutagenicity, and gen-
eral noncancer systemic effects. In this
evaluation, data ofmany sorts were consid-
ered: epidemiological and case study data
from exposed humans, laboratory animal
data for a dozen end points, and in vitro
data for genotoxicity. The remainder of
this discussion will focus on the use of
genotoxicity data in the evaluation of two
important health end points: germ cell
mutagenicity and carcinogenicity.
Methods
Application ofU.S. EPAGuidelines
The U.S. EPA (5) has published guidelines
for classification of potential hazard of
mutagenic effects in human germ cells.
This is a weight-of-evidence process in
which all available information on an agent
is considered. Evidence from human and
animal in vivo and in vitro systems is con-
sidered in the judgment as to the level of
concern or likelihood that an environmen-
tal agent causes heritable damage in germ
cells. In general, the hierarchy ofpreference
for data type is the following: a) data on
germ cells are preferred to data on somatic
cells; b) in vivo tests are preferred to in
vitro; and c) data from tests in eukaryotes
are preferred to data from prokaryotes.
The weight-of-evidence categories
defined in the 1986 guidelines are these,
presented in order ofdecreasing strength of
evidence for human germ cell mutagenicity.
1. Positive data derived from human germ
cell mutagenicity studies.
2. Valid positive results from studies on
heritable mutational events (any kind)
in mammalian germ cells.
3. Valid positive results from mammalian
germ cell chromosome aberration
studies that do not include an intergen-
eration test.
4. Sufficient evidence for a chemical's
interaction with mammalian germ cells,
together with valid positive mutagenic-
ity test results from two assay systems,
at least one ofwhich is mammalian.
The positive results may be both for
gene mutations or both for chromo-
some aberrations; if one is for gene
mutations and the other for chromo-
some aberrations, both must be from
mammalian systems.
5. Suggestive evidence for a chemical's
interaction with mammalian germ cells,
together with valid positive mutagenic-
ity evidence from two assay systems as
described under 4.
6. Positive mutagenicity test results ofless
strength than defined under 4, com-
bined with suggestive evidence for a
chemical's interaction with mammalian
germ cells.
7. Nonmutagenic. Although definitive
proof of nonmutagenicity is not possi-
ble, a chemical could be classified oper-
ationally as a nonmutagen for human
germ cells ifit gives valid negative results
for all end points ofconcern.
8. Not classifiable based on inadequate evi-
dence bearing on either mutagenicity or
chemical interaction with mammalian
germ cells.
To date, no environmental agent has
been conclusively demonstrated to have
caused mutagenic effects in germ cells
in an exposed human population; that
is, no increase in mutation frequency in
a population has been attributed to a
single agent. Thus, there have been no
category 1 mutagens identified. In keep-
ing with the trend in risk assessment for
informative narrative classifications rather
than simple alphanumeric tags, it was
decided for the Mercury Study Report
to Congress to treat these categories as
guidance in assessing a level of concern
for an agent's likelihood to be a germ cell
mutagen. In the report to Congress, three
forms of mercury were discussed in terms
oflevel ofconcern rather than an assigned
numerical category.
According to U.S. EPA (5), a dose-
response assessment ofan agent's potential
for human germ cell mutagenicity can
presently be done using only data from in
vivo heritable germ cell tests. This will
remain the case until such time as other
assays are demonstrated to have an equiva-
lent predictability for human effects. The
usable tests are limited to morphological-
specific locus and biochemical-specific
locus assays and heritable translocation
tests. Data from such assays are generated
from exposures much higher than those
expected for humans as a consequence of
environmental exposure. Estimation of
extent ofhuman risk is done by extrapolat-
ing the observed mutation frequency or
phenotypic effects downward to the
expected human exposure range. Available
data and mechanistic considerations are
used in the choice of the dose-response
model and extrapolation procedure.
The U.S. EPA has generally categorized
the carcinogenic potential of a chemical
based on the overall weight-of-evidence
scheme published in 1986 Guidelines.
The categories and their requirements are
as follows:
Group A: Human Carcinogen.
Sufficient evidence exists from epidemiol-
ogy studies to support a causal association
between exposure to the chemical and
human cancer.
Group B: Probable Human Carcino-
gen. There is sufficient evidence ofcarcino-
genicity in animals with limited (Group
Bi) or inadequate (Group B2) evidence
in humans.
Group C: Possible Human Carcino-
gen. There is limited evidence of carcino-
genicity in animals in the absence of
human data.
Group D: Not Classifiedas to Human
Carcinogenicity. There is inadequate
human and animal evidence of carcino-
genicity or no data are available.
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Group E: Evidence ofNonearcino-
genicityforHumans. There is no evidence
of carcinogenicity in at least two adequate
animal tests in different species or in both
adequate epidemiologic and animal studies.
In the 1986 guidelines, the procedure
was to evaluate first the existing human
and animal data for carcinogenicity ofthe
agent and, based on those data, to assign a
provisional categorization. The second step
was to consider any additional data, which
included an assessment of in vitro and in
vivogenetic toxicology data. After this eval-
uation, the risk assessor could either raise
the level of concern (category) or lower it
based on the results of the other data. In
practical terms, the evaluation ofsupport-
ing data often had little effect on the out-
come of the weight of evidence judgment
for carcinogenicity.
The U.S. EPA has been in the process
of revising its guidelines for cancer risk
assessment. The revised guidelines will
implement the use of narrative categoriza-
tion and will also encourage greater use of
mechanistic data, including information
that can be gained from genetic toxicology.
Data that elucidate the mode of action of
an agent will also have a direct impact on
the dose-response assessment for carcino-
genicity. In the past, a default procedure
for dose-response assessment was most
often followed-that of linear low-dose
extrapolation using an upper bound on the
low-dose term of a linearized multistage
mathematical model. The revised guide-
lines dictate that the type of low-dose
extrapolation to be used, ifany, be guided
by information on the carcinogens mode of
action. Evidence of genetic toxicity has
now become key in making decisions
about dose-response assessment, in partic-
ular whether it is likely that there is a
threshold for effect.
The Mercury Study Report to Congress
was prepared before the revised Carcinogen
Risk Assessment Guidelines were com-
pleted and approved. It was thus necessary
to apply the existing guidelines' alphanu-
meric categories; however, an expanded
narrative was done, and the weight of evi-
dence judgment followed closely the
revised format for expanded consideration
ofmechanistic data.
Results
Background on
Environmental Mercury
Mercury is a pervasive and persistent chem-
ical in the environment. It is a naturally
occurring element that is released from a
variety ofsources including human activi-
ties. Once released into the environment,
mercury undergoes a series of complex
chemical and physical transformations as it
cycles among the atmosphere, land, and
water. Humans, plants, and animals are
routinely exposed to mercury and accumu-
late it during this cycle, potentially result-
ing in a variety of ecological and human
health impacts.
Elemental mercury metal is a liquid
at typical ambient temperatures and pres-
sures; it partitions strongly to air in the
environment. Most ofthe mercury encoun-
tered in the atmosphere is elemental mer-
cury vapor. Mercury can exist in three
oxidation states: Hgo (metallic), Hg22+
(mercurous), and Hg2+ (mercuric). The
properties and behavior ofmercury depend
on the oxidation state. Mercurous and
mercuric mercury can form numerous
inorganic and organic chemical com-
pounds; however, mercurous mercury is
rarely stable under ordinary environmental
conditions. Most of the mercury encoun-
tered in water/soil/sediments/biota (all
environmental media except the atmos-
phere) is in the form ofinorganic mercury
salts and organomercurics.
Mercury is used throughout the world-
wide industrial base because of its diverse
properties. It serves an important role as a
process or product ingredient in several
industrial sectors. In the electrical industry,
mercury is used in components such as
fluorescent lamps, wiring devices and
switches (e.g., thermostats), and mercuric
oxide batteries. Mercury also is used in
navigational devices, instruments that mea-
sure temperature and pressure, and other
related uses. It also is a component ofden-
tal amalgams used in repairing dental caries
(cavities). In addition to specific products,
mercury is used in numerous industrial
processes. The largest quantity ofmercury
used in manufacturing in the United States
is in the production ofchlorine and caustic
soda by mercury cell chlor-alkali plants.
Other processes include amalgamation, use
in nuclear reactors, wood processing (as an
antifungal agent), use as a solvent for reac-
tive and precious metals, and use as a
catalyst. Mercury compounds are also fre-
quently added as a preservative to many
pharmaceutical products.
Three forms of mercury were assessed
in the Mercury Study Report to Congress:
elemental mercury, inorganic mercury, and
methylmercury. They are characterized
by somewhat different biological effects
relevant to human health risk assessment.
Elemental mercury is readily absorbed
through the lungs and may be distributed
throughout the body. Data in experimental
animals are considered sufficient evidence
for developmental effects ofelemental mer-
cury. Evidence from animal tests and from
occupational exposure in humans indicates
that neurotoxicity is the adverse effect most
likely to occur at lowest exposure levels.
Absorption of ingested inorganic mer-
cury is related to the solubility ofthe par-
ticular salt. Data on developmental effects
of inorganic mercury are insufficient for
estimation of the likelihood of human
effects. Systemic toxic effects (rather than
cancer, germ cell mutagenicity, or develop-
mental toxicity) are most likely to occur in
humans as a consequence ofenvironmental
exposures. The sentinel toxic end point
is kidney damage mediated through an
autoimmune effect.
Methylmercury is rapidly and exten-
sively absorbed through the gastrointestinal
tract; once absorbed, it is widely distrib-
uted in the body and across blood-brain
and placental barriers. There are ample data
in humans and animals to consider methyl-
mercury to be a developmental toxicant.
The most important toxic effect ofmethyl-
mercury is on the nervous system. Neuro-
logic abnormalities have been observed in
humans exposed as adults or in utero.
Evaluation ofMercury
forGerm CellMutagenicity
ElementalMercury. Results for an associa-
tion of somatic cell chromosomal effects
with occupational exposure to elemental
mercury are variable. Popescu et al. (6) and
Verschaeve et al. (7) reported increased
incidence of aberrations or aneuploidy.
Most recently, Barregard et al. (8) showed a
significant correlation between cumulative
exposure to elemental mercury and micro-
nuclei induction in T lymphocytes. Nega-
tive results were reported by Verschaeve et
al. (9) and Mabille et al. (10). No studies
ofmutagenic effect, in vitro or in animals,
have been reported.
Absorbed elemental mercury is widely
distributed throughout the body; there are
no data, however, on elemental mercury in
gonadal tissue. Based on both positive and
negative findings for somatic cell chromo-
somal aberrations in workers, the lack of
mutagenicity data, and the lack of evi-
dence that elemental mercury can reach
germ cells, it is placed in a group of low
confidence for potential as a human germ
cell mutagen.
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Inorganic Mercury. There are no data
on inorganic mercury from human germ
cell mutagenicity studies or from studies
on induction of mutations in animals.
Results oftests for mutagenicity have been
variable; generally test results in prokary-
otes are negative for mutagenicity (but may
be positive for DNA damage), and results
in eukaryotes are positive for clastogenicity.
Anwar and Gabal (11) reported a
statistically significant increase by compari-
son to age-matched controls in both chro-
mosomal aberrations and micronuclei in
lymphocytes ofworkers exposed to mer-
cury fulminate. There was a correlation
between frequency of aberrations and
exposure duration.
As summarized by the National
Toxicology Program (NTP) (12) and U.S.
EPA (5), mercuric chloride has produced
some positive results for clastogenicity in a
variety of in vitro and in vivo genotoxicity
assays, but mixed results regarding its
mutagenic activity have been reported.
Mercuric chloride was negative in gene
mutation tests with Salmonella typhi-
murium strains TA1535, TA1537, TA98,
and TA102 with or without hepatic micro-
somal preparations (S9) (13-15). Mercuric
chloride has shown evidence ofDNA dam-
age in the Bacillussubtilis recassay (16) but
did not induce lytic phage in a lysogenic
Escherichia coli strain (17).
Chromosome aberrations were observed
in somatic cells of mice exposed by gavage
(18) and in Chinese hamster ovary (CHO)
cells treated in vitro (12,19). Positive dom-
inant lethal results have been obtained in
studies in which rats were administered
mercuric chloride orally (20). Suter (21)
observed a small but significant increase
in the number of nonviable implants
when female mice were administered mer-
curic chloride by intraperitoneal injection;
this effect was not observed when males
were treated. It was not clear whether the
increase in nonviable implants was due to
maternal toxicity or to a true dominant
lethal effect of the treatment. Sex-linked
recessive lethal mutations were not observed
as a consequence of exposure of male
Drosophila melanogaster by either feeding
or injection (12).
Inorganic mercury is not as well distrib-
uted in the body as elemental mercury;
it does not readily pass blood-brain or
placental barriers. In one reported study
(22), mice treated intraperitoneally were
not shown to have an increased incidence
ofaneuploidy in spermatogonia. Watanabe
et al. (23), however, showed that, while
hamsters injected subcutaneously with
mercuric chloride had no increase in aber-
rations in metaphase II oocytes, there was
detectable mercuric chloride in ovaries and
some inhibition ofovulation.
DNA damage (single strand breaks) has
also been observed in assays using rat and
mouse embryo fibroblasts (20) and CHO
cells and human KB cells (24-32). Mer-
curic chloride also produced chromosome
aberrations and sister chromatid exchange
(SCE) in CHO cells (19) and SCE in
human leukocytes (33). Negative results
for chromosomal aberrations were reported
for FM3A cells (from a mouse mammary
carcinoma) (34) and for two human
diploid lines, W138 and MRC5 (35).
Negative results for SCE were reported for
don cells (36) and for P388D cells, mouse
cells, and CHO cells (37). Evidence of
gene mutations (considered weakly posi-
tive) was observed in L5178Y mouse lym-
phoma cells in the presence ofmicrosomal
preparations (38).
The NTP (12) reached the following
conclusions from their in vitro testing of
mercuric chloride: mercuric chloride was
not mutagenic for Salmonella typhimurium
in preincubation protocols with and with-
out rat and hamster liver preparations; pos-
itive for L5178Y cells without addition of
hepatic preparations; negative for SCE in
CHO cells without addition of S9, but
weakly positive when rat S9 was added;
and positive for chromosomal aberrations
in CHO cells in the absence but not the
presence of liver preparations (it was not
clear what role was played by cytotoxicity
in the generation of these chromosomal
aberrations).
The totality ofavailable data indicates a
moderate weight ofevidence for germ cell
muragenicity for inorganic mercury: sex-
linked recessive and dominant lethal results
were compromised, but there are positive
results for chromosomal aberrations in
multiple systems (including in vivo expo-
sure) and evidence that mercuric chloride
can reach female gonadal tissue.
Methylmercury. Methylmercury
appears to be clastogenic but is not a potent
mutagen. Table 1 gives results from genetic
toxicity testing in vitro. Evidence of DNA
damage has been observed in the Bacillus
subtilis rec assay (16). Kanematsu et al.
(16) reported negative results for methyl-
mercury in spot tests for mutagenicity in
the following bacterial strains: E. coli B/r
WP2 and WP2 and Salmonella typhimur-
ium strains TA1535, TA1537, TA1538,
TA98, and TA100. Jenssen and Ramel
(46), in a review article, indicated that
methylmercury acetate was negative in
both micronucleus assays and in muta-
genicity tests in Salmonella; the authors
referred to Heddle and Bruce (45) and
provided no experimental details. Weak
mutagenic responses for methylmercuric
chloride and methoxyethyl mercury chlo-
ride were observed in Chinese hamsterV79
cells at doses near the cytotoxic threshold
(42), and methylmercury produced a slight
increase in the frequency of chromosomal
nondisjunction in Saccharomyces cerevisiae
(43). Methylmercury, however, caused nei-
ther gene mutations nor recombination in
S. cerevisiae (43). Methylmercury retarded
DNA synthesis and produced single strand
breaks in DNA in L5178Y cells (44).
Methylmercuric chloride and dimethyl-
mercury were both shown to induce chro-
mosome aberrations and aneuploidy
in primary cultures of human lympho-
cytes; methylmercuric chloride was the
more potent clastogen at equally toxic
doses (39). Both methylmercury and
mercuric chloride induced a dose-depen-
dent increase in SCE in primary human
lymphocytes and muntjac fibroblasts;
methylmercury was about five times more
effective in this regard (33,40). Impaired
growth and development was noted in
Table 1. In vitrogenotoxicity of methylmercury.
System Effect References
Primary human lymphocytes Chromosome aberrations, aneuploidy (39)
Primary human lymphocytes SCE (40)
Muntjac fibroblasts SCE (33)
V79, rat glioblastoma cells DNA strand breaks (41)
E. coli B/rWP2, WP2, SalmonellaTAl535, Negative spottest (16)
TAl537, TAl538, TA98, TAl00
V79 cells Weak mutagenicity atcytotoxic dose (42)
Saccharomyces cerevisiae Chromosome nondisjunction, negative for gene (43)
mutations and recombination
L5178Y cells Decreased DNA synthesis, single stand breaks (44)
Micronucleus, Salmonella mutagenicity Negative (45)
Bacillus recassay DNAdamage (16)
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cultured mouse embryonic tissue treated
in vitro with methylmercuric chloride, but
there was no increase in SCE (47). Costa
et al. (41) showed that methylmercuric
chloride caused DNA strand breaks in
both V79 and rat glioblastoma cells
treated in vitro. Methylmercuric chloride
produced more strand breaks than did
mercuric chloride.
Results of studies in humans are given
in Table 2. Studies have reported increased
incidence of chromosome aberrations
(50,51) or SCE (48) in lymphocytes of
humans ingesting mercury-contaminated
fish or meat. A finding of increased fre-
quency of chromosome breaks in workers
was compromised by other concurrent
exposures (6). A study in cats treated in
vivo gave inconsistent results for unsched-
uled DNA synthesis and chromosome
breaks in leukocytes (Table 3).
Other in vivo studies are summarized in
Table 4. Strain-specific differences exist
with respect to the ability of methylmer-
cury to produce dominant lethal effects in
mice (21). When (SECxC57BI)F1 males
were injected with 10 mg/kg methylmer-
cury hydroxide, there was a slight reduc-
tion in the total number of implantations
and a decrease in the number of viable
embryos. This was not observed when
(101 xC3H)FI males were exposed in a
similar fashion. When female (101 x
C3H)F1 mice were treated with methyl-
mercuric hydroxide, no increase in the
incidence of dead implants was observed
(unlike the case for mercuric chloride).
Changes in chromosome number, but no
increase in chromosome aberrations, were
observed in oocytes of Syrian hamsters
treated with one intraperitoneal (ip) injec-
tion of 10 mg/kg methylmercuric chloride
(53). Methylmercury was administered
subcutaneously (sc) to golden hamsters at
doses of 6.4 or 12.8 mg Hg/kg/body
weight. Polyploidy and chromosomal aber-
rations were increased in bone marrow
cells, but there was no effect on metaphase
II oocytes. There was an inhibitory effect
on ovulation, which the authors noted was
not as severe as that induced by mercuric
chloride in the same study (23). Nondis-
junction and sex-linked recessive lethal
mutations were seen in Drosophila melano-
gaster treated with methylmercury in the
diet (54).
Methylmercury is widely distributed
in the body, breaching both blood-brain
and placental barriers in humans. There
are data indicating that methylmercury
administered ip reaches germ cells and
Table 2. Genotoxicity of methylmercury in humans.
Number Exposure Dose
per sex duration (mg/kg/day) Effects, limitations, and BML References
24-63 NS NS Incidence of SCEs in cultured peripheral (48)
(both sexes) lymphocytes correlated with intake of seal meat
in an Eskimo population (as a surrogate for
mercury intake); p= 0.001. Otherfactors also
correlated with SCEs, but multiple regression
analysis found that some of the effect was
attributable to mercury. Limitation: limited exposure
data. BML not reported
51 M Measured as NS Incidence of micronuclei positively correlated (49)
seafood meals with blood mercury concentration and with
perweek; age. No correlation with smoking or number
range = 2-14. of seafood meals per week. Limitation: no control
group. BML range: 10.08-403.11 pg/g blood
18 M exposed; 10.5 year 0.15-0.44 Increased frequency of chromosomal breaks. (6)
10 M control (occupational) (HgCI2) Limitations: workers also exposed to mercuric
chloride and one worker had history of benzene
poisoning; control group was not matched for
sex, smoking habits, or sample size.
BML: = 890 pg/I in urine (average)
6M, 3F >5 year NS Correlation between blood mercury concentration (50)
exposed; 3 M, .3xper week and chromosome breaks in lymphocytes cultured
1 F control from people who ate mercury-contaminated fish.
Limitations: small sample size, limited exposure
data. BML range: 4-650 pg/l in blood
Abbreviations: M, male; F, female; NS, not specified; BML, blood mercury level.
Table 3. Genotoxicity of methylmercury in cats.
Number Exposure Dose
per sex duration (mg/kg/day) Effects, limitations, and BML References
Breed and sex 39 months, 0.008, 0.020, No dose-related changes in unscheduled DNA (52)
not specified 7 days/week 0.046 synthesis in cultured lymphocytes orfrequency
of chromosomal aberrations in bone marrow of
cats fed mercury-contaminated fish or a fish diet
supplemented with methylmercuric chloride.
Limitations: no positive control; no assessment
of cytotoxicity. BML range: 500-13,500 pg/l Hg
in blood
Table 4. Genotoxicity of methylmercury in animals.
Species Exposure Dose
(strain) sex duration (mg/kg/day) Effects and limitations References
Mice, (SECxC57BI)F1, M Once 10 Dominant lethal test; slight reduction (21)
in implantation
Mice, (101 xC3H)F1, M Once 10 Dominant lethal test, no effect (21)
Mice, (101 xC3H)Fj, F Once 10 Dominant lethal test, no effect (21)
Hamster(Syrian) Once, 10 Changes in chromosome number, (53)
intraperitoneal no aberrations in oocytes
Hamster(golden) Once, 6.4 or 12.8 Polyploidy, chromosomal aberrations (23)
subcutaneous in bone marrow, no effect in oocytes;
inhibition of ovulation
Drosophila melanogaster Diet Sex-linked recessives and (54)
nondisjunction
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Table 5. Incidencea of neoplastic lesions in rats in the NTP 2-yeargavage study of mercuric chloride.
Male dose groups(mg Hg/kg/day) Female dose groups (mg Hg/kg/day)
Tumor site and type 0 1.9 3.7 0 1.9 3.7
Forestomach
Papillary hyperplasia 3/49 16/50* 35/50* 5/50 5/49 20/50*
Squamous cell papilloma 0/50 3/50 12/50** 0/50 0/49 2/50
Thyroid follicular cellb
Adenoma 1/50 4/50 0/50
Carcinoma 1/50 2/50 6/50-
Adenoma orcarcinoma 2/50 6/50 6/50
Data from the NTP ( 12). 'Overall rate. bData on thyroid follicular cell lesions were reported for males only.
*p<0.01. **p<0.001; trend test also p<0.001. fp=-0.044, logistic regression.
Table 6. Incidencea of renal tubule tumors in male
mice in the NTP 2-year gavage study of mercuric
chloride.
Dose group (mg/kg/day)
Tumortype 0 5 10
Adenoma 0/50 0/50 2/49
Carcinoma 0/50 0/50 1/49
Adenoma or 0/50 0/50 3/49*
adenocarcinoma
Data from the NTP (12). aOverall rate. *p=0.107; trend
test p=0.032.
may produce adverse effects. Because
there are data for mammalian germ cell
chromosome aberration and limited data
from a heritable mutation study, methyl-
mercury is placed in a group of high
concern for potential human germ cell
mutagenicity. All that keeps methylmer-
cury from the highest level of concern is
the lack of positive results in a heritable
mutation assay.
Assement ofMercury
forCarcinogenicEffects
ElementalMercury. Human data regard-
ing the carcinogenicity of inhalation of
elemental mercury are insufficient to
determine whether such exposures may
result in increased cancer incidence. Several
studies report statistically significant
increases in lung cancer mortality among
groups of exposed workers (55-58). The
interpretation ofthese studies is limited by
small sample sizes, probable exposure to
other known lung carcinogens, failure to
consider confounders such as smoking,
and failure to observe correlations between
estimated exposure and the cancer inci-
dence. A study of dental professionals
found a significant increase in the inci-
dence of glioblastomas (59). It is not
known whether exposure to mercury, X
rays, or other potential carcinogens in the
workplace contributed to the effects
observed. No increase in cancer mortality
was observed among workers exposed to
mercury vapor in a nuclear weapons facil-
ity (60), but this study was also limited by
the small sample size. No studies were
identified that examined cancer incidence
in animals exposed chronically to elemental
mercury vapor.
The overall findings from genetic toxic-
ity testing (described above) are very lim-
ited and point to clastogenicity in workers
occupationally exposed to mercury by
inhalation. There are no reported tests for
gene mutation.
In summary, human epidemiological
studies failed to show a correlation between
exposure to elemental mercury vapor and
increased cancer incidence, but the studies
are limited by confounding factors. Only
one study in animals is reported (61):
tumors were found only at contact sites,
and the study is incompletely reported as to
controls and statistics. Animal data are also
inadequate. Findings from assays for geno-
toxicity are limited and provide no convinc-
ing evidence that mercury exposure has an
effect on the number or structure ofchro-
mosomes in human somatic cells. The most
appropriate category is, thus, Group D, not
classifiable as to human carcinogenicity.
Inorganic Mercury. There are no data
available on the carcinogenic effects of
inorganic mercury (mercuric chloride) in
humans. In animals, there is equivocal evi-
dence of carcinogenicity in rats and mice
(Table 5). In rats gavaged with mercuric
chloride for 2 years (12), survival was
significantly reduced in males (17 and 8%
survival in low- and high-dose males,
respectively, versus 43% survival in con-
trols), indicating that the maximally
tolerated dose (MTD) was exceeded. There
was an increased incidence of forestom-
ach squamous cell papillomas. Papillary
hyperplasia of the forestomach was also
significantly elevated in both male dose
groups and in high-dose females. In addi-
tion, the incidence ofthyroid follicular cell
carcinomas in treated males showed a
significantly positive trend. There were,
however, no increases in thyroid hyperpla-
sia of adenomas; it is not clear that the
increase in thyroid carcinomas is a treat-
ment-related effect. The NTP considered
the forestomach tumors to be oflimited
relevance to humans; there was no evidence
that these contact site tumors progressed
to malignancy.
In a companion study in mice (12),
there was a significantly increased trend for
renal tubular cell tumors (adenomas and
adenomacarcinomas). This is presented in
Table 6. No dose groups were statistically
significantly different from the control by
pair-wise comparison, although the inci-
dence in the high-dose group was elevated.
There was a significant increase in severe
nephropathy in treated animals.
In summary, there are no data in
humans linking mercuric chloride with
carcinogenic effects, and data in animals
are limited. Focal hyperplasia and squa-
mous cell papillomas of the forestomach,
as well as thyroid follicular adenomas and
carcinomas, were observed in male rats
gavaged with mercuric chloride (12). In
the same study, evidence for increased
incidence of squamous cell forestomach
papillomas in female rats and renal adeno-
mas and carcinomas in male mice were
considered equivocal. All increased tumor
incidences were observed at what were
considered high doses (in excess of the
MTD). In this context, the relevance ofthe
thyroid tumor to human health evaluation
has been questioned; these tumors are
considered to be secondary to the hyper-
plastic response. Results from in vitroand in
vivo tests for genotoxicity have been mixed;
there is no clear indication of a strong
mutagenic effect in somatic cells. This lack
of a mutagenic effect supports a judgment
oflimited data for carcinogenicity.
Methylmercury. The available human
data are inconclusive regarding the carcino-
genicity of methylmercury in humans
exposed by the oral route. A study of leu-
kemia patients from a rural area in Poland
showed a significantly higher mercury con-
tent in hair in the leukemia patients than
in healthy unrelated patients or healthy rel-
atives (62). The population studied was
small, and the study did not adjust for
other leukemia risk factors. In addition,
two studies oflarger populations exposed
to methylmercury during the Minamata
incident failed to show increases in leu-
kemia or total cancer incidence (63,64).
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Table 7. Carcinogenic effects of methylmercury in animals: oral exposure.
Species (strain)
number per sex Exposure duration Dose (mg/kg/day) Effects, limitations, and BML References
Rat (strain NS) 25 M, 25 F 2 year, adlibitum in feed 0, 0.004, 0.02, 0.1 Tumors at comparable incidence in all groups. Limitations: small (65)
sample size; failure to achieve MTD. BML average: 850 pg/l in
blood at 0.004, 6,500 pg/I at 0.02, and 36,000-39,000 pg/l at 0.1
Rat (Sprague Dawley) 56 M,56 F 130 week adlibitum in feed M: 0.011, 0.05, 0.28; No increase in tumor incidence. (66,67)
F: 0.014, 0.064, 0.34
Mice (Swiss) 54 M, 54 F From weaning until death 0, 0.19, 0.19-0.95 No increase in gross tumor incidence. Limitation: histological (68)
in drinking water examination not performed.
Mouse (ICR) 60 M, 60 F 78 week adlibitum in feed 0, 1.6, 3.1 Increased incidence of renal adenomas and adenocarcinomas in (69)
low-dose males. Limitations: very poor survival in both male
dose groups.
Mouse (ICR) 60 M, 60 F 104 week adlibitum in feed 0, 0.02, 0.03,0.11, Incidence of renal epithelial adenocarcinoma significantly increased (70)
0.15, 0.6, 0.73 in males at 0.73; not invasive. Limitations: MTD exceeded (including
severe renal damage in high-dose males).
Mouse(B6C3F,) 60 M, 60 F 2 year, adlibitum in feed M: 0.03, 0.14, 0.69; Renal epithelial carcinomas and adenomas in males at 0.69. (71)
F: 0.03, 0.13, 0.6 Limitation: MTD exceeded in high-dose males.
Mice (Swiss) NS 15 week adlibitum in 0, 0.03, 0.07, 0.27 Number of lung adenomas/mouse and tumor size/mouse increased (72)
drinking water with dose.
Cat (domestic) 4-5 M, 4-5 F 2 year, adlibitum in feed 0, 0.0084, 0.02, No increase in tumor incidence. Limitations: small group size, short (73)
0.046, 0.074, 0.176 exposure duration, no pathological data forthree lowest doses.
Abbreviations: NS, not specified, M, male; F, female.
Although one of these studies showed a
significant increase in liver cancer inci-
dence, factors other than mercury exposure
were likely contributors to the increase.
Animal studies show some evidence of
carcinogenicity in two strains of mice, but
studies in rats have not shown similar
results (Table 7). Male ICR mice given
methylmercuric chloride in the diet for up
to 2 years had significantly increased inci-
dences of renal epithelial adenomas and
adenocarcinomas (69,70). Similarly, male
B6C3Fl mice given methylmercuric
chloride in the diet for up to 2 years had
significantly increased incidences of renal
epithelial carcinomas and adenomas (71).
In contrast, Sprague-Dawley rats adminis-
tered methylmercury in the diet for up to
130 weeks exhibited no increase in tumor
incidence (66,67). Although the dose was
lower in the rats than in the mice, a maxi-
mally tolerated dose was achieved in the rat
study as evidenced by an approximately 20
to 30% decrease in body weight gain and
by significant increases in renal and neu-
ronal toxicity in both male and female rats
at the highest dose tested. Other studies
also failed to show increases in tumor inci-
dence after chronic exposure to methyl-
mercury (65,68), but these studies were
limited by small sample sizes, failure to
achieve a maximally tolerated dose, and/or
incomplete histopathological examinations.
In summary, data for carcinogenicity
from human studies are considered inade-
quate. Three studies that examined the
relationship between methylmercury expo-
sure in humans and increased incidence of
cancer were limited by poor study designs
or incomplete descriptions ofmethodology
or results. Data from animal studies are
considered to provide limited evidence
ofcarcinogenicity.
Male ICR and B6C3F1 mice exposed
to methylmercuric chloride in the diet
were observed with increased incidence of
renal adenomas, adenocarcinomas, and car-
cinomas. Tumors were observed at a single
site in a single species and sex. Renal epi-
thelial cell hyperplasia and tumors were
observed only in the presence ofprofound
nephrotoxicity; tumors were suggested to
be consequent to reparative changes in the
affected organs. Genotoxicity test data sug-
gest that methylmercury is clastogenic
rather than mutagenic. The lack ofa strong
mutagenic response does not raise the
overall level of concern and supports the
weight-of-evidence judgment oflimited data
or Group C, possible human carcinogen.
Dose-ResponseAssessment
forMercury
Data do not support the generation of
quantitative estimates for germ cell muta-
genicity for any form ofmercury. Methyl-
mercury was considered to have a high
level of concern for the likelihood that it
could be a human germ cell mutagen. The
data for methylmercury all point to the
probability that it acts as a clastogen and
does not cause point mutations. There are
not sufficient dose-response data for
genetic toxicity ofmethylmercury to sup-
port a low-dose extrapolation for human
germ cell effects. Moreover, there is a great
deal of uncertainty as to the appropriate
model to be applied to an agent that acts as
a clastogen in the absence of observable
point mutation activity.
Elemental mercury is categorized as
Group D, unable to be classified as to
human carcinogenicity. A quantitative
estimate for carcinogenic effect is, thus,
inappropriate.
Quantification ofthe potential carcino-
genic effects of mercuric chloride was not
done. The data on squamous cell papillomas
of the forestomach and thyroid follicular
cell carcinomas from the NTP (12) were
evaluated for suitability as a basis for low-
dose extrapolation. The forestomach
tumors in this assay were not used because
these particular tumors were probably the
result of irritation of the forestomach, cell
death, and epithelial proliferation. Because
the carcinogenic mechanism may be specific
to irritation at the high doses used in the
bioassay, use ofthese tumors as a basis for
human health assessment of low doses of
inorganic mercury is inappropriate.
Regarding the thyroid carcinomas, a
variety ofdrugs, chemicals, and physiologi-
cal perturbations result in the development
ofthyroid follicular tumors in rodents. For
a number ofchemicals, the mechanism of
tumor development appears to be a sec-
ondary effect oflongstanding hypersecre-
tion of thyroid-stimulating hormone by
the pituitary (74,75). In the absence of
such long-term stimulatory effects, induc-
tion of thyroid follicular cell cancer by
such chemicals usually does not occur
(76). Use of the incidence of thyroid
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tumors from the NTP (12) in low-dose
extrapolation is therefore questionable. The
lack ofa mutagenic effect likewise calls into
question the application of a linear low-
dose model. The use of linear low-dose
models is based on a hypothesis for car-
cinogenicity that predicates an irreversible
first step in a multistep process. This first
step is usually considered to be one involv-
ing mutagenicity as an irreversible change
at the genome level.
Quantification ofthe potential carcino-
genic effects ofmethylmercury (classified as
Group C, possible human carcinogen) was
not done; only renal epithelial tumors in
male mice were reported to be increased.
The two studies by Mitsumori et al.
(69,71) were limited by high mortality in
the high-dose males, the only group to
exhibit a statistically significant increase in
tumor incidence. The study by Hirano
et al. (70) was not limited by survival
problems, but the tumors were observed in
conjunction with nephrotoxicity and
appear to be a high-dose phenomenon that
may not be linear at low doses. The tumors
appeared to originate from focal hyperpla-
sia ofthe tubular epithelium induced as a
reparative change. The hyperplasia was not
observed in tubular epithelium that was
undergoing early degenerative changes;
thus, the tumors may not occur where
degenerative changes do not occur. The
appropriateness ofderiving a quantitative
risk estimate using the assumption oflin-
earity at low doses based on data for which
a threshold may exist is questionable. The
lack ofa mutagenic response in the absence
ofclastogenicity also argues against linear
low-dose extrapolation.
Summary and Discussion
All three species of mercury were assessed
for their potential to cause mutations
in germ cells using the Guidelines for
Mutagenicity Risk Assessment (5). Ele-
mental mercury was placed in a category of
low confidence for potential as a human
germ cell mutagen. This is based on reports
of both positive and negative findings for
chromosomal aberrations in somatic cells
ofexposed workers. There are no reports
of assays for mutagenicity of elemental
mercury. While absorbed elemental mer-
cury is widely distributed throughout the
body, there are no data on the presence of
elemental mercury in rodent gonadal tissue.
The somewhat more complete database
for inorganic mercury indicates a moderate
weight of evidence for germ cell muta-
genicity. Sex-linked recessive mutations
were not observed in Drosophila melano-
gaster, and dominant lethal assays in mice
were compromised by maternal toxicity.
There were, however, positive results for
chromosomal aberrations in multiple sys-
tems including in vivo exposure in occupa-
tionally exposed humans and in somatic
cells of gavaged mice. There is evidence
that mercuric chloride can reach gonadal
tissue (oocytes) but no evidence ofdamage
to that tissue.
Because there are data for mammalian
germ cell chromosomal damage and limited
data from a heritable mutation study,
methylmercury was placed in a group of
high concern for potential human germ cell
mutagenicity. All that keeps methylmercury
from the highest level ofconcern is lack of
positive results in a heritable mutation assay
such as the mouse specific locus test. Data
do not support quantitative estimates of
germ cell mutagenicity. The effects noted
have been chromosomal damage and
dominant lethal effects at levels which also
produced maternal toxicity. There is no
evidence of mutagenic effects at less than
toxic doses.
Available data on carcinogenic activity
and related experimental end points were
evaluated for elemental mercury, mercuric
mercury, and methylmercury. According to
U.S. EPA's Guidelines for Carcinogen Risk
Assessment (77), elemental mercury is cate-
gorized as Group D, unable to be classified
as to human carcinogenicity. Human epi-
demiologic studies failed to show a correla-
tion between exposure to elemental mercury
vapor and increased cancer incidence, but
these studies were limited for interpreta-
tion by confounding factors. Only one
inadequate study in animals has been
reported. Findings from assays for genotox-
icity were limited and did not provide con-
vincing evidence that elemental mercury
causes mutations or chromosomal effects.
Mercuric mercury (inorganic mercury)
has been categorized as Group C, possible
human carcinogen, according to the U.S.
EPA Guidelines for Carcinogen Risk
Assessment (77). There are no data on the
carcinogenic effects of inorganic mercury
in humans. In animals there is equivocal
evidence of carcinogenicity in rats and
mice reported by NTP (12). Focal hyper-
plasia and squamous cell papillomas ofthe
forestomach, as well as thyroid follicular
adenomas and carcinomas, were observed
in male rats gavaged with mercuric chlo-
ride. The relevance ofthe thyroid tumors to
evaluation ofpotential human risk has been
questioned; these tumors are considered to
be secondary to the hyperplastic response.
Evidence for increased incidence ofsqua-
mous cell forestomach papillomas in
female rats and renal tubule adenomas and
carcinomas in male mice was considered
equivocal. All increased tumor incidences
were observed at what were considered to
be high doses; that is, in excess of the
MTD. Results from in vitro and in vivo
tests for genotoxicity have been mixed,
with no clear indication ofproduction of
gene mutations by inorganic mercury
administered at less than toxic doses.
Methylmercury has also been catego-
rized as Group C, possible human carcino-
gen, according to the U.S. EPA Guidelines
for Carcinogen RiskAssessment (77). Data
from human studies were considered inad-
equate. Three studies on the relationship
between methylmercury exposure in
humans and increased cancer incidence
were limited by poor study designs or
incomplete descriptions ofmethodology or
results. Data from animal studies were con-
sidered to be limited. Male ICR and
B6C3F1 mice exposed to methylmercury
in the diet had increased incidences of
renal adenomas, adenocarcinomas, and
carcinomas. These were found only in the
presence ofprofound nephrotoxicity and
were suggested to be consequent to repara-
tive changes in the damaged organ. MTDs
were exceeded in studies in which increased
tumor incidence was observed. Results
from genotoxicity tests indicated evidence
for clastogenicity, but not for mutagenic-
ity, and did not support raising the level of
concern for methylmercury as a low-dose
human carcinogen.
The current U.S. EPA cancer guide-
lines indicate that for agents classified as
Group C, possible human carcinogen, a
quantitative risk estimate should be consid-
ered on a case-by-case basis. No quantita-
tive estimation of low-dose cancer risk
from either inorganic mercury or methyl-
mercury (both categorized as Group C,
possible human carcinogen) has been done.
Modes ofaction for both forms ofmercury
were not linked to processes such as gene
mutation, for which a model employing
low-dose linearity would be plausible.
The data are too limited to permit use ofa
nonlinear low-dose estimation.
It is likely that systemic noncancer
effects for both inorganic and methylmer-
curywould be seen at exposures lower than
those required for tumor formation. Long-
term administration ofmethylmercury to
experimental animals produces either
neurotoxic signs or overt neurotoxicity at
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Table 8. Lowest observed adverse effect levels (LOAELs) for methylmercury toxicity-chronic animal studies, oral
administration.
End point Species (strain) sex LOAEL(pg/kg-day) References
Renal tumors Mice (ICR) male 730 (70)
Renal tumors Mice (B6C3F1) male 690 (71)
Neurotoxicity (loss oftactile response) Cynomolgus monkeys 50 (78)
Neurotoxicity Cats (outbred) NS 46 (73)
Neurotoxicity, decreased hemoglobin, hematocrit Rats (Wistar) male 25 (79)
NS, not specified.
daily doses an order of magnitude lower
than those which induce cancer in mice
(Table 8). More sensitive measures applied
to humans exposed for a relatively short
duration have been the basis of a lowest
observed adverse effect level (LOAEL) of
3.0 pg/kg/day methylmercury for pares-
thesia in adults. A benchmark dose (95%
lower confidence limit on 10% risk) of
1.1 Ipg/kg/day has been calculated for
composite neurological end points in
offspring of 81 exposed women from the
Iraq poisoning incident (80). It is likely
that a quantitative assessment such as a
reference dose, based on either the human
benchmark or LOAEL, would be protec-
tive against potential carcinogenic hazard
from methylmercury.
In summary, it is likely that in the near
future genetic toxicity information on envi-
ronmental agents will play an enhanced
role in their risk assessment. This is due
to two trends in overall characterization of
human risk. The first is the move to a more
integrated or holistic approach to human
health risk evaluation, which considers end
points other than cancer as important to
understanding the magnitude and type of
potential hazard. The second trend is in
the increased emphasis on mechanistic data
in the assessment ofan agent's potential to
be a human carcinogen. The ability to
assess the totality ofa material's genotoxic-
ity database will clearly be an asset in the
application of risk assessment principles
to the evaluation of hazards relevant to
human health.
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